SCHEMBL1355761

SCHEMBL1355761

Cc1ccc(N)c(CNc2nc(NC(C)CC(C)(C)O)nc3c2ncn3C(C)C)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 17/20 0.64
▸ CCNE1 P24864 16/20 0.64
▸ CDK5 Q00535 9/20 0.64
▸ CDK7 P50613 9/20 0.64
▸ CDK9 P50750 8/20 0.64
▸ CCNH P51946 8/20 0.64
▸ CCNT1 O60563 7/20 0.64
▸ CDK5R1 Q15078 6/20 0.64
▸ CCNT2 O60583 3/20 0.60
▸ CCNE2 O96020 3/20 0.60
▸ CDK1 P06493 11/20 0.54
▸ CCNB1 P14635 8/20 0.52
▸ CDK4 P11802 7/20 0.52
▸ CCND1 P24385 4/20 0.52
▸ CDK3 Q00526 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ CCNB2 O95067 3/20 0.50
▸ CCNB3 Q8WWL7 3/20 0.50
▸ CASK O14936 1/20 0.50
▸ CCNA2 P20248 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355193 0.93 CDK2 (0.64) CDK2CCNE1CDK5CDK7CDK9
SCHEMBL1355039 0.91 CDK2 (0.67) CDK2CCNE1CDK5CDK7CDK9
SCHEMBL1354939 0.90 CDK2 (0.63) CDK2CCNE1CDK5CDK7CDK9
SCHEMBL1352527 0.90 CDK2 (0.63) CDK2CCNE1CDK5CDK7CDK9
SCHEMBL1354702 0.90 CDK2 (0.69) CDK2CCNE1CDK5CDK7CDK9
SCHEMBL1353779 0.90 CDK2 (0.78) CDK2CCNE1CDK5CDK7CDK9
SCHEMBL1354586 0.90 CDK2 (0.51) CDK2CCNE1CDK5CDK7CDK9
SCHEMBL15118162 0.90 CDK2 (0.73) CDK2CCNE1CDK5CDK7CDK9
SCHEMBL1354721 0.89 CCNE1 (0.61) CDK2CCNE1CDK5CDK7CDK9
SCHEMBL1354147 0.89 CCNE1 (0.68) CDK2CCNE1CDK5CDK7CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9023857-B2 Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2015-05-05 — — US claimed
EP-2391626-B1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS Univerzita Palackého v Olomouci (CZ) 2014-10-01 — — EP claimed
EP-2391626-A2 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS Univerzita Palackého v Olomouci (CZ) 2011-12-07 — — EP claimed
US-20110287111-A1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2011-11-24 — — US claimed
WO-2010085924-A2 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2010-08-05 — — WO claimed
US-9023857-B2 Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2015-05-05 — — US disclosed
EP-2391626-B1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS Univerzita Palackého v Olomouci (CZ) 2014-10-01 — — EP disclosed
EP-2391626-A2 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS Univerzita Palackého v Olomouci (CZ) 2011-12-07 — — EP disclosed
US-20110287111-A1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2011-11-24 — — US disclosed
WO-2010085924-A2 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2010-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110287111-A1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS CDK6, CCNI, CDK2 CDK2 3/4885CCNE1 55/4885CDK5 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback